AbbVie Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends

SG&A Expense Trends: AbbVie Inc. vs Iovance Biotherapeutics, Inc.

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of industry giants is crucial. Over the past decade, AbbVie Inc. and Iovance Biotherapeutics, Inc. have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AbbVie Inc. has seen a significant increase in SG&A expenses, peaking at approximately $15.3 billion in 2022, a 98% rise from 2016. This reflects their aggressive market expansion and strategic investments. In contrast, Iovance Biotherapeutics, Inc., a smaller player, has steadily increased its SG&A expenses, reaching around $107 million in 2023, marking a tenfold increase since 2014. This growth underscores their commitment to scaling operations and enhancing market presence. As these companies navigate the competitive biotech sector, their SG&A trends offer valuable insights into their operational priorities and market strategies.